Medullary thyroid carcinoma identified within the first year of life in children with hereditary multiple endocrine neoplasia type 2A (codon 634) and 2B

European Journal of Endocrinology

Volumn 160, Issue 5, 2009, Pages 807-813

  Zenaty, D ^a   Aigrain, Y ^b   Peuchmaur, M ^b   Philippe Chomette, P ^b   Baumann, C ^b   Cornelis, F ^c   Hugot, J P ^b   Chevenne, D ^b   Barbu, V ^d   Guillausseau, P J ^c   Schlumberger, M ^e   Carel, J C ^a   Travagli, J P ^e   Léger, Juliane ^a  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b HÔPITAL ROBERT DEBRÉ   (France)

^c HÔPITAL LARIBOISIÈRE   (France)

^d HÔPITAL SAINT ANTOINE   (France)

^e INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITONIN; CALCIUM; LEVOTHYROXINE; PARATHYROID HORMONE; PENTAGASTRIN;

ARTICLE; CALCITONIN BLOOD LEVEL; CALCIUM BLOOD LEVEL; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CODON; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GENETIC SCREENING; HORMONE SUBSTITUTION; HOSPITAL BASED CASE CONTROL STUDY; HUMAN; LIFE EXPECTANCY; LYMPH NODE DISSECTION; MALE; MICROMETASTASIS; NEUROFIBROMATOSIS; PARATHYROID HORMONE BLOOD LEVEL; PRIORITY JOURNAL; SIPPLE SYNDROME; THYROID HORMONE BLOOD LEVEL; THYROID MEDULLARY CARCINOMA; THYROIDECTOMY; CASE REPORT; EVALUATION; FAMILY; FOLLOW UP; GENETICS; INFANT; MEDULLARY CARCINOMA; NEWBORN; NEWBORN SCREENING; PRESCHOOL CHILD; THYROID TUMOR;

CARCINOMA, MEDULLARY; CHILD; CHILD, PRESCHOOL; CODON; FAMILY; FEMALE; FOLLOW-UP STUDIES; GENETIC SCREENING; HUMANS; INFANT; INFANT, NEWBORN; MALE; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2B; NEONATAL SCREENING; THYROID NEOPLASMS; THYROIDECTOMY;

EID: 65549112520     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-08-0854     Document Type: Article

References (35)

1. Mulligan LM, Kwok JB, Healey CS, Elsdon MJ, Eng C, Gardner E, Love DR, Mole SE, Moore JK, Papi L, Ponder MA, Telenius H, Tunnacliffe A & Ponder BAJ. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 1993 363 458-460.
2. Hofstra RM, Landsvater RM, Ceccherini I, Stulp RP, Stelwagen T, Luo Y, Pasini B, Hoppener JW, van Amstel HK, Romeo G, Lips CJM & Buys CHCM. A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature 1994 367 375-376.
3. Santoro M, Carlomagno F, Romano A, Bottaro DP, Dathan NA, Grieco M, Fusco A, Vecchio G, Matoskova B & Kraus MH. Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B. Science 1995 267 381-383.
4. Wolfe HJ, Melvin KE, Cervi-Skinner SJ, Saadi AA, Juliar JF, Jackson CE & Tashjian AH Jr. C-cell hyperplasia preceding medullary thyroid carcinoma. New England Journal of Medicine 1973 289 437-441.
5. Cunliffe WJ, Hudgson P, Fulthorpe JJ, Black MM, Hall R, Johnston ID & Shuster S. A calcitonin-secreting medullary thyroid carcinoma associated with mucosal neuromas, marfanoid features, myopathy and pigmentation. American Journal of Medicine 1970 48 120-126.
6. Keiser HR, Beaven MA, Doppman J, Wells S Jr & Buja LM. Sipple's syndrome: medullary thyroid carcinoma, pheochromocytoma, and parathyroid disease. Studies in a large family. NIH conference. Annals of Internal Medicine 1973 78 561-579.
7. Farndon JR, Leight GS, Dilley WG, Baylin SB, Smallridge RC, Harrison TS & Wells SA Jr. Familial medullary thyroid carcinoma without associated endocrinopathies: a distinct clinical entity. British Journal of Surgery 1986 73 278-281.
8. Eng C, Clayton D, Schuffenecker I, Lenoir G, Cote G, Gagel RF, van Amstel HK, Lips CJ, Nishisho I, Takai SI, Marsh DJ, Robinson BG, Frank-Raue K, Raue F, Xue F, Noll WW, Romei C, Pacini F, Fink M, Niederle B, Zedenius J, Nordenskjold M, Komminoth P, Hendy GN & Mulligan LM. The relationship between specific RET protooncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. Journal of the American Medical Association 1996 276 1575-1579.
9. Brandi ML, Gagel RF, Angeli A, Bilezikian JP, Beck-Peccoz P, Bordi C, Conte-Devolx B, Falchetti A, Gheri RG, Libroia A, Lips CJ, Lombardi G, Mannelli M, Pacini F, Ponder BA, Raue F, Skogseid B, Tamburrano G, Thakker RV, Thompson NW, Tomassetti P, Tonelli F, Wells SA Jr & Marx SJ. Guidelines for diagnosis and therapy of MEN type 1 and type 2. Journal of Clinical Endocrinology and Metabolism 2001 86 5658-5671.
10. Niccoli-Sire P, Murat A, Rohmer V, Franc S, Chabrier G, Baldet L, Maes B, Savagner F, Giraud S, Bezieau S, Kottler ML, Morange S & Conte-Devolx B. Familial medullary thyroid carcinoma with noncysteine ret mutations: phenotype-genotype relationship in a large series of patients. Journal of Clinical Endocrinology and Metabolism 2001 86 3746-3753.
11. Machens A, Niccoli-Sire P, Hoegel J, Frank-Raue K, van Vroonhoven TJ, Roeher HD, Wahl RA, Lamesch P, Raue F, Conte-Devolx B & Dralle H. Early malignant progression of hereditary medullary thyroid cancer. New England Journal of Medicine 2003 349 1517-1525.
12. Skinner MA, Moley JA, Dilley WG, Owzar K, Debenedetti MK & Wells SA Jr. Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A. New England Journal of Medicine 2005 353 1105-1113.
13. De Groot JW, Links TP, Plukker JT, Lips CJ & Hofstra RM. RET as a diagnostic and therapeutic target in sporadic and hereditary endocrine tumors. Endocrine Reviews 2006 27 535-560.
14. Niccoli-Sire P, Murat A, Rohmer V, Gibelin H, Chabrier G, Conte-Devolx B, Visset J, Ronceray J, Jaeck D, Henry JF, Proye C, Carnaille B & Kraimps JL. When should thyroidectomy be performed in familial medullary thyroid carcinoma gene carriers with non-cysteine RET mutations? Surgery 2003 134 1029-1036.
15. Kahraman T, de Groot JW, Rouwe C, Hofstra RM, Links TP, Sijmons RH & Plukker JT. Acceptable age for prophylactic surgery in children with multiple endocrine neoplasia type 2a. European Journal of Surgical Oncology 2003 29 331-335.
16. Piolat C, Dyon JF, Sturm N, Pinson S, Bost M, Jouk PS, Plantaz D & Chabre O. Very early prophylactic thyroid surgery for infants with a mutation of the RET proto-oncogene at codon 634: evaluation of the implementation of international guidelines for MEN type 2 in a single centre. Clinical Endocrinology 2006 65 118-124.
17. Unruh A, Fitze G, Janig U, Bielack S, Lochbuhler H & Coerdt W. Medullary thyroid carcinoma in a 2-month-old male with multiple endocrine neoplasia 2B and symptoms of pseudo-Hirschsprung disease: a case report. Journal of Pediatric Surgery 2007 42 1623-1626.
18. Leboulleux S, Travagli JP, Caillou B, Laplanche A, Bidart JM, Schlumberger M & Baudin E. Medullary thyroid carcinoma as part of a multiple endocrine neoplasia type 2B syndrome: influence of the stage on the clinical course. Cancer 2002 94 44-50.
19. Modigliani E, Cohen R, Campos JM, Conte-Devolx B, Maes B, Boneu A, Schlumberger M, Bigorgne JC, Dumontier P, Leclerc L, Corcuff B & Guilhem I. Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. The GETC study group. Clinical Endocrinology 2003 48 265-273.
20. Szinnai G, Meier C, Komminoth P & Zumsteg UW. Review of multiple endocrine neoplasia type 2A in children: therapeutic results of early thyroidectomy and prognostic value of codon analysis. Pediatrics 2003 111 132-139.
21. Scheuba C, Kaserer K, Bieglmayer C, Asari R, Riss P, Drosten R & Niederle B. Medullary thyroid microcarcinoma recommendations for treatment-a single-center experience. Surgery 2007 142 1003-1010.
22. Machens A, Schneyer U, Holzhausen HJ & Dralle H. Prospects of remission in medullary thyroid carcinoma according to basal calcitonin level. Journal of Clinical Endocrinology and Metabolism 2005 90 2029-2034.
23. Frank-Raue K, Buhr H, Dralle H, Klar E, Senninger N, Weber T, Rondot S, Hoppner W & Raue F. Long-term outcome in 46 gene carriers of hereditary medullary thyroid carcinoma after prophylactic thyroidectomy: impact of individual RET genotype. European Journal of Endocrinology 2006 155 229-236.
24. Verga U, Morpurgo PS, Vaghi I, Radetti G & Beck-Peccoz P. Normal range of calcitonin in children measured by a chemiluminescent two-site immunometric assay. Hormone Research 2006 66 17-20.
25. Scollo C, Baudin E, Travagli JP, Caillou B, Bellon N, Leboulleux S & Schlumberger M. Rationale for central and bilateral lymph node dissection in sporadic and hereditary medullary thyroid cancer. Journal of Clinical Endocrinology and Metabolism 2003 88 2070-2075.
26. Sanso GE, Domene HM, Garcia R, Pusiol E, de M, Roque M, Ring A, Perinetti H, Elsner B, Iorcansky S & Barontini M. Very early detection of RET proto-oncogene mutation is crucial for preventive thyroidectomy in multiple endocrine neoplasia type 2 children: presence of C-cell malignant disease in asymptomatic carriers. Cancer 2002 94 323-330.
27. BrauckhoffM, Gimm O,Weiss CL, Ukkat J, Sekulla C, Brauckhoff K, Thanh PN & Dralle H. Multiple endocrine neoplasia 2B syndrome due to codon 918 mutation: clinical manifestation and course in early and late onset disease. World Journal of Surgery 2004 28 1305-1311.
28. Jackson MB, Guttenberg M, Hedrick H & Moshang T Jr. Multiple endocrine neoplasia type 2A in a kindred with C634Y mutation. Pediatrics 2005 116 468-471.
29. Machens A, Ukkat J, Brauckhoff M, Gimm O & Dralle H. Advances in the management of hereditary medullary thyroid cancer. Journal of Internal Medicine 2005 257 50-59.
30. Punales MK, Graf H, Gross JL & Maia AL. RET codon 634 mutations in multiple endocrine neoplasia type 2: variable clinical features and clinical outcome. Journal of Clinical Endocrinology and Metabolism 2003 88 2644-2649.
31. Baudin E, Travagli JP & Schlumberger M. How effective is prophylactic thyroidectomy in asymptomatic multiple endocrine neoplasia type 2A? Nature Clinical Practice. Endocrinology and Metabolism 2006 2 256-257.
32. Machens A, Hauptmann S & Dralle H. Increased risk of lymph node metastasis in multifocal hereditary and sporadic medullary thyroid cancer. World Journal of Surgery 2007 31 1960-1965.
33. Machens A, Hauptmann S & Dralle H. Medullary thyroid cancer responsiveness to pentagastrin stimulation: an early surrogate parameter of tumor dissemination? Journal of Clinical Endocrinology and Metabolism 2008 93 2234-2238.
34. Niccoli P, Wion-Barbot N, Caron P, Henry JF, de Micco C, Saint Andre JP, Bigorgne JC, Modigliani E & Conte-Devolx B. Interest of routine measurement of serum calcitonin: study in a large series of thyroidectomized patients. The French Medullary Study Group. Journal of Clinical Endocrinology and Metabolism 1997 82 338-341.
35. Machens A, Hofmann C, Hauptmann S & Dralle H. Locoregional recurrence and death from medullary thyroid carcinoma in a contemporaneous series: 5-year results. European Journal of Endocrinology 2007 157 85-93.